Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

DNA variations in genes increase risk of developing PI-IBS

Studies of the victims of the Walkerton, Ont. tainted drinking water tragedy have led researchers to discover DNA variations in genes that increase the risk of developing post-infectious irritable bowel syndrome (PI-IBS). The sheer scale of infection and the recording of the health of Walkerton's citizens gave a team of researchers a unique opportunity to study the origin of this disorder.

28 Jan 2010

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.

20 Jan 2010

Over-the-counter medications can help manage minor ailments

Nonprescription medications in the home medicine cabinet could save a trip to the doctor. The January issue of Mayo Clinic Health Letter lists more than a dozen over-the-counter medications that can help manage minor ailments.

18 Jan 2010

Alterations in intestinal microbiota may lie behind IBS aetiology

Irritable bowel syndrome (IBS) is a common gastrointestinal functional disorder that can greatly affect the patient's well being. Multiple interacting mechanisms, including alterations in the intestinal microbiota, are suspected to lie behind IBS aetiology.

18 Jan 2010

Findings suggest abuse is a risk factor for chronic headache

Researchers from the American Headache Society's Women's Issues Section Research Consortium found that incidence of childhood maltreatment, especially emotional abuse and neglect, are prevalent in migraine patients.

5 Jan 2010

St. John's wort not effective in treating IBS

A Mayo Clinic research study published in the January issue of the American Journal of Gastroenterology finds that St. John's wort is not an effective treatment for irritable bowel syndrome (IBS). While antidepressants are frequently used to treat IBS, to date, no study has examined the success of using the herbal supplement St. John's wort in treating IBS.

5 Jan 2010

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Neurocrine Biosciences, Inc. today announced their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-98854, will be advanced in clinical development.

21 Dec 2009

Immuno Laboratories and TRPN sign agreement to reduce chronic illness

Immuno Laboratories, a leading provider of food and environmental allergy testing services, announced an agreement with Three Rivers Provider Network (TRPN), the largest and fastest growing proprietary Preferred Provider Organization (PPO) network in the United States.

18 Dec 2009

Neurocrine Biosciences to sell 4,784,689 shares of common stock to Venrock affiliates

Neurocrine Biosciences, Inc. today reported that it has entered into a privately negotiated transaction to sell an aggregate of 4,784,689 primary shares of its common stock to affiliates of Venrock at a price of $2.09 per share, raising aggregate gross proceeds to Neurocrine of approximately $10 million. Neurocrine expects the financing to close on or about December 22, 2009, subject to customary closing conditions.

17 Dec 2009

Drop in U.S. colorectal cancer deaths

The American Society for Gastrointestinal Endoscopy (ASGE) lauds the recent news of the decline in U.S. colorectal cancer death and incidence rates. The report, released this week, shows that from 1975 to 2000, incidence rates dropped 22 percent and death rates dropped 26 percent.

10 Dec 2009

Salix Pharmaceuticals discusses proposed rifaximin NDA with the FDA

Salix Pharmaceuticals, Ltd. today reported that the Company held a pre-NDA meeting on December 8, 2009 with the FDA to discuss the Company’s proposed new drug application (NDA) for rifaximin in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS).

10 Dec 2009

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from the Tulip PETAL Study (703 Study), its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

10 Dec 2009

PEG polymer may prevent GI injury during cancer radiotherapy

A non-absorbed, oral co-polymer therapy under development by Midway Pharmaceuticals demonstrated the ability to protect against damage to healthy gastrointestinal tissues and to prevent lethal bacterial infections in animal models of radiation damage.

3 Dec 2009

Burrill Biotech Select Index manages to claw back almost half the value it lost in October

The Burrill Biotech Select Index managed to claw back almost half the value it lost in October. The Select's gain of 4.5 percent mirrored what was also an excellent month for the general markets with the Dow up 6.5 percent and the NASDAQ up 4.8 percent in value.

2 Dec 2009

MicroDose Therapeutx acquires a portfolio of compounds from Epix Pharmaceuticals

MicroDose Therapeutx Inc. today announced that it has acquired a portfolio of compounds for the potential treatment of chronic constipation, irritable bowel syndrome with constipation (IBS-C) and other diseases, from Epix Pharmaceuticals, Inc. (EPIX) (Lexington, MA).

2 Dec 2009

Additional data on lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting

Sucampo Pharma Europe, Ltd., and Sucampo Pharma Americas, Inc., subsidiaries of Sucampo Pharmaceuticals, Inc., today presented additional clinical data for lubiprostone (Amitiza®) at GASTRO 2009 UEGF/WCOG, the joint meeting of the United European Gastroenterology Federation (UEGF), the World Gastroenterology Organisation (WGO), the World Organisation of Digestive Endoscopy (OMED) and the British Society of Gastroenterology (BSG), in London.

25 Nov 2009

Top-line data from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS to be presented

Lexicon Pharmaceuticals, Inc., announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon's senior vice president of clinical development, on November 25, 2009 at 2:30 pm local time at the session entitled, "Therapeutic insights in functional digestive disorders."

23 Nov 2009

Swissmedic grants marketing authorization for Amitiza

Sucampo Pharma Europe Ltd., a subsidiary of Sucampo Pharmaceuticals, Inc., today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza® (lubiprostone) 24 microgram (mcg) gel capsules for the long-term treatment of patients with chronic idiopathic constipation (CIC).

20 Nov 2009

Gastrointestinal symptoms may interfere with nutritional management of ED patients

Eating disorders (ED) patients display a high prevalence of gastrointestinal symptoms and functional gastrointestinal disorders such as irritable bowel syndrome. These symptoms may interfere with their nutritional management. Ingestion of fructose-sorbitol (F-S) is an established means of gastrointestinal symptom provocation in irritable bowel syndrome patients.

20 Nov 2009

Albireo completes A3309 phase 1b study in patients with chronic idiopathic constipation

Albireo today announced the completion of a phase 1b study showing a favorable tolerability and safety profile of A3309 in patients with chronic idiopathic constipation. In addition, the data revealed appropriate efficacy signals in this patient population. A3309 is a first in class compound developed for the treatment of chronic idiopathic constipation and constipation-predominant Irritable Bowel Syndrome (IBS-C).

18 Nov 2009

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

DNA variations in genes increase risk of developing PI-IBS

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Over-the-counter medications can help manage minor ailments

Alterations in intestinal microbiota may lie behind IBS aetiology

Findings suggest abuse is a risk factor for chronic headache

St. John's wort not effective in treating IBS

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Immuno Laboratories and TRPN sign agreement to reduce chronic illness

Neurocrine Biosciences to sell 4,784,689 shares of common stock to Venrock affiliates

Drop in U.S. colorectal cancer deaths

Salix Pharmaceuticals discusses proposed rifaximin NDA with the FDA

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

PEG polymer may prevent GI injury during cancer radiotherapy

Burrill Biotech Select Index manages to claw back almost half the value it lost in October

MicroDose Therapeutx acquires a portfolio of compounds from Epix Pharmaceuticals

Additional data on lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting

Top-line data from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS to be presented

Swissmedic grants marketing authorization for Amitiza

Gastrointestinal symptoms may interfere with nutritional management of ED patients

Albireo completes A3309 phase 1b study in patients with chronic idiopathic constipation

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in